Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
Consequently, shares of Incyte were down 9% on Nov. 18 in after-market trading. Shares of Incyte have risen 5.4% year to date against the industry's 11.1% decline. Image Source: Zacks Investment Research Incyte announced that it will pause enrollment in the ongoing phase II study of MRGPRX2 in CSU due to certain in vivo preclinical toxicology findings. The data was also shared with the FDA. The company is now working closely with the FDA to determine the next steps. Additionally, data from the phase II study evaluating MRGPRX4 in cholestatic pruritus does not support further development. Meanwhile, enrollment in the other INCB000262 proof-of-concept studies is complete. Data from all studies will help support its future development and guide the potential growth of backup molecules. Incyte's lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea; interm
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- INCY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Incyte Corporation investmentAccesswire
- Incyte Co. (NASDAQ: INCY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Incyte Co. (NASDAQ: INCY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Lost Money on Incyte Corporation(INCY)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationAccesswire
- Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study [Yahoo! Finance]Yahoo! Finance
INCY
Earnings
- 10/29/24 - Beat
INCY
Sec Filings
- 11/8/24 - Form SC
- 11/8/24 - Form 4
- 11/6/24 - Form 144
- INCY's page on the SEC website